Brief: Allena Pharmaceuticals Commences Dosing Of Gout Patients In Second Phase 2A Trial Of ALLN-346
29/09/2021 13:41
Sept 29 (Reuters) - Allena Pharmaceuticals Inc ALNA.O :
* ALLENA PHARMACEUTICALS COMMENCES DOSING OF GOUT PATIENTS
IN
SECOND PHASE 2A TRIAL OF ALLN-346
* ALLENA PHARMACEUTICALS INC - INITIAL DATA EXPECTED IN LATE
2021
OR EARLY 2022
Source text for Eikon: ID:nGNXbVLb9B
Further company coverage: ALNA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allena Pharmaceuticals
See all newsBrief: Allena Pharmaceuticals Inc - On September 6, Received Notice From Nasdaq That Its Shares Will Be Suspended At Open Of Business On September 8, 2022
U.S. STOCKS ON THE MOVE-Relmada, Entera Bio, Eli Lilly
U.S. STOCKS ON THE MOVE-ChannelAdvisor, HyreCar, ADT, miners
U.S. STOCKS ON THE MOVE-Timken, Bed Bath & Beyond, HyreCar, chip stocks
Allena down on bankruptcy filing